Pierre Grammond

5.7k total citations
6 papers, 96 citations indexed

About

Pierre Grammond is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Pierre Grammond has authored 6 papers receiving a total of 96 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pathology and Forensic Medicine, 2 papers in Neurology and 2 papers in Oncology. Recurrent topics in Pierre Grammond's work include Multiple Sclerosis Research Studies (6 papers), Peripheral Neuropathies and Disorders (2 papers) and Polyomavirus and related diseases (2 papers). Pierre Grammond is often cited by papers focused on Multiple Sclerosis Research Studies (6 papers), Peripheral Neuropathies and Disorders (2 papers) and Polyomavirus and related diseases (2 papers). Pierre Grammond collaborates with scholars based in Australia, Kuwait and Italy. Pierre Grammond's co-authors include Helmut Butzkueven, Raed Alroughani, Jeannette Lechner‐Scott, Pierre Duquette, Alessandra Lugaresi, Tim Spelman, Michael Barnett, María Trojano, François Grand’Maison and Eugenio Pucci and has published in prestigious journals such as Journal of Neurology Neurosurgery & Psychiatry, Multiple Sclerosis Journal and European Journal of Neurology.

In The Last Decade

Pierre Grammond

6 papers receiving 92 citations

Peers

Pierre Grammond

PFM

NEURO

ONCOL

RHEUM

PHEOH

Sara Eichau Spain

N A Malkova Russia

Mayu Saito Japan

Sara Montepietra Italy

Richard Greil Austria

Simon Rule United Kingdom

Pegah Farrokhi Iran

Patti L. Pierce Tate United States

Audrey Clarissa Indonesia

Susana Merino Spain

Sara Eichau Spain

Pierre Grammond

48 ×0.5

PFM

21 ×0.6

NEURO

15 ×0.5

ONCOL

12 ×0.6

RHEUM

9 ×0.7

PHEOH

Citations per year, relative to Pierre Grammond Pierre Grammond (= 1×) peers Sara Eichau

Countries citing papers authored by Pierre Grammond

Since Specialization

Citations

This map shows the geographic impact of Pierre Grammond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Grammond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Grammond more than expected).

Fields of papers citing papers by Pierre Grammond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Grammond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Grammond. The network helps show where Pierre Grammond may publish in the future.

Co-authorship network of co-authors of Pierre Grammond

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Grammond. A scholar is included among the top collaborators of Pierre Grammond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Grammond. Pierre Grammond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Signori, Alessio, Marta Ponzano, Tomáš Kalinčík, et al.. (2024). Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. Journal of Neurology Neurosurgery & Psychiatry. 95(7). 620–625. 2 indexed citations

2.

Malpas, Charles B., Izanne Roos, Sifat Sharmin, et al.. (2022). Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation. 42(4). 355–364. 9 indexed citations

3.

Spelman, Tim, Dana Horáková, Serkan Özakbaş, et al.. (2022). Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity. Multiple Sclerosis and Related Disorders. 70. 104477–104477. 1 indexed citations

4.

Kister, Ilya, Tim Spelman, Raed Alroughani, et al.. (2016). Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology Neurosurgery & Psychiatry. 87(10). 1133–1137. 64 indexed citations

5.

Spelman, Tim, Therese Burke, Helmut Butzkueven, et al.. (2016). Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology. 23(4). 729–736. 17 indexed citations

6.

Gray, Orla, David Jolley, Jeannette Lechner‐Scott, et al.. (2009). The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis. Multiple Sclerosis Journal. 15(1). 140–140. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact